Codexis Inc (CDXS) 3.42 $CDXS
Codexis to Present at BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 3:27PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that President and CEO John Nicols and Senior Vice President and CFO Gordon Sangster will present at the 17 Annual BIO CEO & Investor Conference on Monday, February 9, 2015, at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). The conference is being held at the Waldorf Astoria in New York City.
CDXS: 3.42 (+0.07)
Codexis (CDXS) Jumps: Stock Adds 8.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:11AM CST
Codexis, Inc. (CDXS) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
CDXS: 3.42 (+0.07), ABGB: 15.52 (+0.34)
Codexis Uses Its CodeEvolver(R) Protein Engineering Platform Technology to Develop an Enzyme Therapeutic Candidate for the Potential Treatment of Phenylketonuria (PKU) via Oral Administration
GlobeNewswire - Wed Dec 03, 5:38PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that it has developed a novel enzyme therapeutic product candidate for the potential treatment of phenylketonuria (PKU) via oral administration. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. As a result, phenylalanine accumulates in high levels in the brain causing serious neurological problems, including intellectual disability, seizures and cognitive and behavioral problems. Phenylalanine is found in many foods, including meat, dairy products, fish, poultry and many fruits and vegetables.
CDXS: 3.42 (+0.07)
Global Synthetic Biology Market 2013-2020 - Opportunities and Forecasts for the $38 Billion Market
M2 - Thu Nov 27, 6:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/g34xgv/global_synthetic) has announced the addition of the "Global Synthetic Biology Market (Products, Technologies, Applications and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The global synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020) Key factors fueling the growth of this market include assistance from government and private organizations, rising number of entities conducting research and declining cost of DNA sequencing and synthesizing. Bio-safety & bio-security and ethical issues are key restraining factors of the market. The fact that synthetic biology can be misused has raised concerns all around the world. However, as far as the market dynamics are considered, the bottom line is that the overall impact of these factors would be highly positive. Global synthetic biology market is segmented based on product, technology, application, and geography. Synthetic biology product market is further segmented into enabling products, enabled products and core products. Enabling product is the fastest growing segment in the product market due to ongoing researches that may bring-innovative ideas for application of synthetic biology in new fields. Thus, the need for enabling products, during R&D activities and in the development of enabled products, would rise. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Synthetic Biology Market By Product Chapter 5 Global Synthetic Biology Market By Technologies Chapter 6 Global Synthetic Biology Market By Application Chapter 7 Synthetic Biology Market By Geography Chapter 8 Company Profiles - Algenol Biofuels - BASF - BioAmber - BioSearch Technologies - Butamax Advanced Biofuels - Codexis Inc. - Dupont - GEN9 Inc. - Gensript Corporation - Origene Technologies - Synthetic Genomics For more information visit http://www.researchandmarkets.com/research/g3..._synthetic
CDXS: 3.42 (+0.07)
Codexis to Present at the LD Micro Main Event VII Conference on December 4
GlobeNewswire - Tue Nov 25, 7:07AM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will provide a corporate update at the LD Micro Main Event VII Conference, being held December 2-4, 2014 at The Luxe Hotel in Los Angeles, California.
CDXS: 3.42 (+0.07)
Insider Trading Alert - ITG, CDXS And ARQL Traded By Insiders
at The Street - Fri Nov 21, 1:45PM CST
Stocks with insider trader activity include ITG, CDXS and ARQL
ITG: 21.99 (-0.19), ARQL: 1.35 (+0.04), CDXS: 3.42 (+0.07)
Codexis' (CDXS) CEO John Nicols on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:50PM CST
CDXS: 3.42 (+0.07)
Codexis misses by $0.06, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:09PM CST
CDXS: 3.42 (+0.07)
Codexis Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2014
GlobeNewswire - Tue Nov 04, 3:03PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced financial results for the third quarter and nine months ended September 30, 2014.
CDXS: 3.42 (+0.07)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.09 (+0.30), ITRI: 35.75 (-0.12), AWAY: 29.68 (+0.11), OKE: 47.32 (+0.04), HR: 28.69 (-0.08), NYMT: 7.75 (+0.05), OCLR: 1.55 (+0.09), ENPH: 15.15 (+0.37), ADEP: 6.93 (-0.30), CBSO: 27.51 (+0.58), NSTG: 12.66 (-0.11), MITT: 18.52 (+0.08), CRTO: 40.70 (+0.41), FOXA: 34.72 (+0.31), OKS: 45.47 (+0.07), JMBA: 14.50 (-0.61), IVR: 15.33 (+0.01), CSU: 24.59 (+0.03), MYGN: 34.03 (+0.40), JIVE: 5.34 (+0.02), GAS: 50.07 (+0.27), COUP: 11.06 (-0.07), NRP: 7.86 (-0.45), MOSY: 2.10 (+0.02), COHR: 64.95 (+0.25), DOX: 51.15 (+0.37), CKEC: 29.96 (+0.89), OAS: 16.84 (-0.03), PAYC: 32.37 (-0.71), PCYC: 163.28 (+0.23), AXLL: 47.40 (+0.51), NP: 62.15 (-0.52), BIRT: 6.60 (+0.01), ATVI: 23.11 (+0.17), EXAM: 39.97 (+0.31), P: 15.44 (+0.45), JAZZ: 169.69 (+6.89), PBPB: 13.92 (-0.07), EXEL: 2.48 (+0.20), CERS: 5.53 (+0.08), DVN: 66.47 (+0.69), FEYE: 42.26 (+2.63), CHUY: 22.04 (-0.35), FRGI: 61.80 (-0.33), GHDX: 31.12 (+0.28), PACD: 3.76 (+0.16), BIO: 118.36 (+0.79), BIOL: 2.22 (+0.22), JKHY: 65.78 (+0.52), KAR: 35.64 (-0.03), CDXS: 3.42 (+0.07), MPO: 1.00 (-0.02), FANG: 73.46 (+0.49), CORT: 3.15 (+0.01), CALD: 14.95 (+0.03)
Codexis Appoints Pam P. Cheng, Merck Global Executive, to Board of Directors
GlobeNewswire - Mon Nov 03, 3:01PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Pam Cheng to its board of directors. Ms. Cheng is a 17-year veteran of Merck & Co. and is currently serving as President of MSD China, where she has direct responsibility for $1.3 billion in sales and approximately 4,000 employees, covering a wide functional scope which includes commercial, R&D, manufacturing and various business support organizations.
MRK: 58.81 (-0.07), CDXS: 3.42 (+0.07)
Industrial Enzymes: Carbohydrases, Proteases, Lipases & Others - 2014 Global Strategic Business Report
M2 - Wed Oct 29, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrwq4b/industrial) has announced the addition of the "Industrial Enzymes - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Industrial Enzymes in US$ Thousands by the following Product Segments: - Carbohydrases - Proteases - Lipases - Others The report also analyzes the following End-Use Segments: - Food & Beverage - Detergents & Other Cleaning Products - Textiles - Animal Feed - Ethanol Production - Others The report profiles 52 companies including many key and niche players such as: - AB Enzymes GmbH - Advanced Enzyme Technologies Ltd. - Amano Enzyme Inc. - Asahi Kasei Pharma Corporation - BASF SE - BioResource International, Inc. - Chr. Hansen A/S - Codexis, Inc. - DuPont Nutrition and Health - Direvo Biotech AG - Enzymatic Deinking Technologies LLC - Hayashibara Company - Novozymes A/S - Royal DSM Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competition 3. Market Trends, Issues And Drivers 4. Product Overview 5. Product Introductions/Innovations 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. The Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 52 (including Divisions/Subsidiaries - 60) - The United States (18) - Canada (1) - Japan (3) - Europe (29) - - France (7) - - Germany (7) - - The United Kingdom (2) - - Spain (1) - - Rest of Europe (12) - Asia-Pacific (Excluding Japan) (
- Latin America (1) For more information visit http://www.researchandmarkets.com/research/hrwq4b/industrial
CDXS: 3.42 (+0.07)
Codexis reports November 4
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 7:39AM CDT
CDXS: 3.42 (+0.07)
Codexis to Report Third Quarter 2014 Financial Results on November 4
GlobeNewswire - Tue Oct 21, 7:11AM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will report third quarter financial results after the close of market on November 4, followed at 4:30 p.m. Eastern Time by a conference call and audio webcast at www.codexis.com.
CDXS: 3.42 (+0.07)
Market Maker Surveillance Report. AHPI, APT, LAKE, IBIO, CDXS, MPO, Losing Stocks With Lowest Price Friction For Tuesday, October 14th 2014
M2 - Wed Oct 15, 3:11AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4904 companies with "abnormal" market making, 2632 companies with positive Friction Factors and 2319 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Allied Healthcare Products Inc (NASDAQ:AHPI), Alpha Pro Tech Ltd (NYSE:APT), Lakeland Industries Inc (NASDAQ:LAKE), Ibio Inc (NYSE:IBIO), Codexis Inc (NASDAQ:CDXS), Midstates Petroleum Company Inc (NYSE:MPO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
APT: 2.88 (+0.17), AHPI: 1.56 (unch), MPO: 1.00 (-0.02), CDXS: 3.42 (+0.07), IBIO: 0.90 (+0.36), LAKE: 10.18 (+0.89)
Codexis Appoints Biotechnology Industry Veteran, Kathleen Glaub, to Board of Directors
GlobeNewswire - Mon Sep 22, 7:07AM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Kathleen Sereda Glaub to its board of directors. Ms. Glaub's 30-year career in leadership positions with drug development and technology companies will bring strong company-building and business strategy experience to the Codexis board.
CDXS: 3.42 (+0.07)
Analyzing the Market for Cellulosic Ethanol - 2014
M2 - Wed Sep 17, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/38rww8/analyzing_the) has announced the addition of the "Analyzing the Market for Cellulosic Ethanol - 2014" report to their offering. This report is a complete handbook on this dynamic fuel source and its position in the global energy scenario. The report builds on the global energy industry and the consumption patterns which are fed by the traditional sources like Oil, Coal, Natural Gas, Nuclear Energy and Hydroelectricity. The report also presents a track on the global energy consumption patterns along with the resources being used for them. Taking into consideration the revenue cycles in the global energy markets, the report explains the revenue derived from these demand patterns from traditional sources as well as hydroelectric and wind energy. The report further also details each source individually. Taking a contrasting view point the report presents an in depth analysis of the global energy crisis and the growing recognition of unconventional energy sources for arresting this crisis. Key Topics Covered: A. Executive Summary B. Analyzing the Global Energy Industry C. Revenue Returns on Global Energy Markets D. Global Energy Demand & Supply Dynamics E. Looking at the Global Energy Crisis F. Emergence of Ethanol as an Energy Source G. Introduction to Cellulosic Ethanol H. Analyzing the Major Conversion Technologies: Producing Ethanol from Cellulosic Feedstocks I. Analyzing Ethanol Production from Different Feedstocks J. Analyzing the Utility of Ethanol in Transportation K. Commercializing Cellulosic Ethanol L. Factors Impact Growth of the Industry M. Challenges & Issues Facing the Industry N. Technological Patterns Prominent in the Industry O. Role of Industrial Biotechnology in the Development of Cellulosic Ethanol P. Production Patterns Q. Influence of Cellulosic Ethanol on the Farm Economy R. Ethanol Production and Use - Impact on the Economy S. Analyzing the Economics of Ethanol Production T. Analyzing the Regulatory Framework U. Government Incentives & Support Mechanisms V. Leading Industry Players - Abengoa Bioenergy Corporation - Archer Daniels Midland Co. - Aventine Renewable Energy Holdings - Cargill - Codexis, Inc - Dyadic International, Inc - Genencor International - Green Plains Renewable Energy. - Iogen Corporation - Lignol - Mascoma Corporation - NatureWorks, LLC - Novozymes - Pacific Ethanol, Inc. - Renova Energy (Wyoming Ethanol) - SunOpta - Tate & Lyle - The Andersons Inc. - U.S. BioEnergy Corporation - VeraSun Energy Corporation - Verenium - Xethanol BioFuels, LLC For more information visit http://www.researchandmarkets.com/research/38...lyzing_the
ADM: 48.10 (+0.66), GPRE: 25.50 (-0.56), CDXS: 3.42 (+0.07)
Global Synthetic Biology Market Forecasts and Opportunities, 2020
M2 - Tue Sep 02, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnnz65/global_synthetic) has announced the addition of the "Global Synthetic Biology Market (Products, Technologies, Applications and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. Global synthetic biology market was valued at $3.0 billion in 2013 and it is estimated to reach $38.7 billion by 2020, growing at a CAGR of 44.2% during the forecast period. Synthetic biology is a novel field that finds its origin at the intersection of biology and engineering. It involves designing and construction of biological systems or devices that can be applied in varied domains to get specified results. It's a multidisciplinary effort made by scientists to understand the functioning of biological organisms, cells & genes and implementation of artificial genetic processes to give specific characteristics to an organism. It can even be used to develop a completely new biological system. Assistance from government and private organizations, rising number of entities conducting research and declining cost of DNA sequencing and synthesizing are key driving factors of the market. Governments are providing funds to research organizations, assisting them to find novel applications of synthetic biology. Bio-safety & bio-security issues, ethical issues and regulations are key retraining factors of the market. The fact that synthetic biology can be misused has raised concerns all around the world. Further, there are possibilities of accidental release of pathogens or genetically modified organisms into free atmosphere. Report Scope Key Deliverables Market by Products - Enabling Products - DNA Synthesis - Oligonucleotide Synthesis - Enabled Products - Pharmaceuticals - Chemicals - Biofuels - Agriculture - Core Products - Synthetic DNA - Synthetic Genes - Synthetic Cells - XNA - Chassis Organisms Market by Technology - Enabling Technology - Genome Engineering - Microfluidics technologies - DNA synthesis & sequencing technologies - Bioinformatics technologies - Biological components and integrated systems technologies - Enabled Technology - Pathway engineering - Synthetic microbial consortia - Biofuels technologies Market by Application Research & Development - Chemicals - Agriculture - Pharmaceuticals & Diagnostics - Biofuels - Others (Environment, Biotechnology & Biomaterials, etc.) Companies Mentioned - Algenol Biofuels - BASF - BioAmber - BioSearch Technologies - Butamax Advanced Biofuels - Codexis Inc. - Dupont - GEN9 Inc. - Gensript Corporation - Origene Technologies - Synthetic Genomics For more information visit http://www.researchandmarkets.com/research/jn..._synthetic
CDXS: 3.42 (+0.07)
Codexis Reports Financial Results for the Second Quarter of 2014
GlobeNewswire - Wed Aug 06, 3:02PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced its financial results for the second quarter ended June 30, 2014.
CDXS: 3.42 (+0.07)
5 Stocks Ready for Breakouts
at The Street - Mon Aug 04, 9:14AM CDT
These stocks are within range of triggering breakout trades.
BLUE: 90.70 (+0.93), TSLA: 203.77 (+0.89), ZPIN: 16.16 (-0.16), OVTI: 27.30 (unch), CDXS: 3.42 (+0.07), ATRO: 57.27 (+2.72)
Codexis to Present at BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 3:27PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that President and CEO John Nicols and Senior Vice President and CFO Gordon Sangster will present at the 17 Annual BIO CEO & Investor Conference on Monday, February 9, 2015, at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). The conference is being held at the Waldorf Astoria in New York City.
CDXS: 3.42 (+0.07)
Codexis (CDXS) Jumps: Stock Adds 8.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:11AM CST
Codexis, Inc. (CDXS) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
CDXS: 3.42 (+0.07), ABGB: 15.52 (+0.34)
Codexis Uses Its CodeEvolver(R) Protein Engineering Platform Technology to Develop an Enzyme Therapeutic Candidate for the Potential Treatment of Phenylketonuria (PKU) via Oral Administration
GlobeNewswire - Wed Dec 03, 5:38PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that it has developed a novel enzyme therapeutic product candidate for the potential treatment of phenylketonuria (PKU) via oral administration. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. As a result, phenylalanine accumulates in high levels in the brain causing serious neurological problems, including intellectual disability, seizures and cognitive and behavioral problems. Phenylalanine is found in many foods, including meat, dairy products, fish, poultry and many fruits and vegetables.
CDXS: 3.42 (+0.07)
Global Synthetic Biology Market 2013-2020 - Opportunities and Forecasts for the $38 Billion Market
M2 - Thu Nov 27, 6:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/g34xgv/global_synthetic) has announced the addition of the "Global Synthetic Biology Market (Products, Technologies, Applications and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The global synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020) Key factors fueling the growth of this market include assistance from government and private organizations, rising number of entities conducting research and declining cost of DNA sequencing and synthesizing. Bio-safety & bio-security and ethical issues are key restraining factors of the market. The fact that synthetic biology can be misused has raised concerns all around the world. However, as far as the market dynamics are considered, the bottom line is that the overall impact of these factors would be highly positive. Global synthetic biology market is segmented based on product, technology, application, and geography. Synthetic biology product market is further segmented into enabling products, enabled products and core products. Enabling product is the fastest growing segment in the product market due to ongoing researches that may bring-innovative ideas for application of synthetic biology in new fields. Thus, the need for enabling products, during R&D activities and in the development of enabled products, would rise. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Synthetic Biology Market By Product Chapter 5 Global Synthetic Biology Market By Technologies Chapter 6 Global Synthetic Biology Market By Application Chapter 7 Synthetic Biology Market By Geography Chapter 8 Company Profiles - Algenol Biofuels - BASF - BioAmber - BioSearch Technologies - Butamax Advanced Biofuels - Codexis Inc. - Dupont - GEN9 Inc. - Gensript Corporation - Origene Technologies - Synthetic Genomics For more information visit http://www.researchandmarkets.com/research/g3..._synthetic
CDXS: 3.42 (+0.07)
Codexis to Present at the LD Micro Main Event VII Conference on December 4
GlobeNewswire - Tue Nov 25, 7:07AM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will provide a corporate update at the LD Micro Main Event VII Conference, being held December 2-4, 2014 at The Luxe Hotel in Los Angeles, California.
CDXS: 3.42 (+0.07)
Insider Trading Alert - ITG, CDXS And ARQL Traded By Insiders
at The Street - Fri Nov 21, 1:45PM CST
Stocks with insider trader activity include ITG, CDXS and ARQL
ITG: 21.99 (-0.19), ARQL: 1.35 (+0.04), CDXS: 3.42 (+0.07)
Codexis' (CDXS) CEO John Nicols on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:50PM CST
CDXS: 3.42 (+0.07)
Codexis misses by $0.06, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:09PM CST
CDXS: 3.42 (+0.07)
Codexis Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2014
GlobeNewswire - Tue Nov 04, 3:03PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced financial results for the third quarter and nine months ended September 30, 2014.
CDXS: 3.42 (+0.07)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.09 (+0.30), ITRI: 35.75 (-0.12), AWAY: 29.68 (+0.11), OKE: 47.32 (+0.04), HR: 28.69 (-0.08), NYMT: 7.75 (+0.05), OCLR: 1.55 (+0.09), ENPH: 15.15 (+0.37), ADEP: 6.93 (-0.30), CBSO: 27.51 (+0.58), NSTG: 12.66 (-0.11), MITT: 18.52 (+0.08), CRTO: 40.70 (+0.41), FOXA: 34.72 (+0.31), OKS: 45.47 (+0.07), JMBA: 14.50 (-0.61), IVR: 15.33 (+0.01), CSU: 24.59 (+0.03), MYGN: 34.03 (+0.40), JIVE: 5.34 (+0.02), GAS: 50.07 (+0.27), COUP: 11.06 (-0.07), NRP: 7.86 (-0.45), MOSY: 2.10 (+0.02), COHR: 64.95 (+0.25), DOX: 51.15 (+0.37), CKEC: 29.96 (+0.89), OAS: 16.84 (-0.03), PAYC: 32.37 (-0.71), PCYC: 163.28 (+0.23), AXLL: 47.40 (+0.51), NP: 62.15 (-0.52), BIRT: 6.60 (+0.01), ATVI: 23.11 (+0.17), EXAM: 39.97 (+0.31), P: 15.44 (+0.45), JAZZ: 169.69 (+6.89), PBPB: 13.92 (-0.07), EXEL: 2.48 (+0.20), CERS: 5.53 (+0.08), DVN: 66.47 (+0.69), FEYE: 42.26 (+2.63), CHUY: 22.04 (-0.35), FRGI: 61.80 (-0.33), GHDX: 31.12 (+0.28), PACD: 3.76 (+0.16), BIO: 118.36 (+0.79), BIOL: 2.22 (+0.22), JKHY: 65.78 (+0.52), KAR: 35.64 (-0.03), CDXS: 3.42 (+0.07), MPO: 1.00 (-0.02), FANG: 73.46 (+0.49), CORT: 3.15 (+0.01), CALD: 14.95 (+0.03)
Codexis Appoints Pam P. Cheng, Merck Global Executive, to Board of Directors
GlobeNewswire - Mon Nov 03, 3:01PM CST
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Pam Cheng to its board of directors. Ms. Cheng is a 17-year veteran of Merck & Co. and is currently serving as President of MSD China, where she has direct responsibility for $1.3 billion in sales and approximately 4,000 employees, covering a wide functional scope which includes commercial, R&D, manufacturing and various business support organizations.
MRK: 58.81 (-0.07), CDXS: 3.42 (+0.07)
Industrial Enzymes: Carbohydrases, Proteases, Lipases & Others - 2014 Global Strategic Business Report
M2 - Wed Oct 29, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrwq4b/industrial) has announced the addition of the "Industrial Enzymes - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Industrial Enzymes in US$ Thousands by the following Product Segments: - Carbohydrases - Proteases - Lipases - Others The report also analyzes the following End-Use Segments: - Food & Beverage - Detergents & Other Cleaning Products - Textiles - Animal Feed - Ethanol Production - Others The report profiles 52 companies including many key and niche players such as: - AB Enzymes GmbH - Advanced Enzyme Technologies Ltd. - Amano Enzyme Inc. - Asahi Kasei Pharma Corporation - BASF SE - BioResource International, Inc. - Chr. Hansen A/S - Codexis, Inc. - DuPont Nutrition and Health - Direvo Biotech AG - Enzymatic Deinking Technologies LLC - Hayashibara Company - Novozymes A/S - Royal DSM Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competition 3. Market Trends, Issues And Drivers 4. Product Overview 5. Product Introductions/Innovations 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. The Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 52 (including Divisions/Subsidiaries - 60) - The United States (18) - Canada (1) - Japan (3) - Europe (29) - - France (7) - - Germany (7) - - The United Kingdom (2) - - Spain (1) - - Rest of Europe (12) - Asia-Pacific (Excluding Japan) (
- Latin America (1) For more information visit http://www.researchandmarkets.com/research/hrwq4b/industrial CDXS: 3.42 (+0.07)
Codexis reports November 4
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 7:39AM CDT
CDXS: 3.42 (+0.07)
Codexis to Report Third Quarter 2014 Financial Results on November 4
GlobeNewswire - Tue Oct 21, 7:11AM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will report third quarter financial results after the close of market on November 4, followed at 4:30 p.m. Eastern Time by a conference call and audio webcast at www.codexis.com.
CDXS: 3.42 (+0.07)
Market Maker Surveillance Report. AHPI, APT, LAKE, IBIO, CDXS, MPO, Losing Stocks With Lowest Price Friction For Tuesday, October 14th 2014
M2 - Wed Oct 15, 3:11AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4904 companies with "abnormal" market making, 2632 companies with positive Friction Factors and 2319 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Allied Healthcare Products Inc (NASDAQ:AHPI), Alpha Pro Tech Ltd (NYSE:APT), Lakeland Industries Inc (NASDAQ:LAKE), Ibio Inc (NYSE:IBIO), Codexis Inc (NASDAQ:CDXS), Midstates Petroleum Company Inc (NYSE:MPO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
APT: 2.88 (+0.17), AHPI: 1.56 (unch), MPO: 1.00 (-0.02), CDXS: 3.42 (+0.07), IBIO: 0.90 (+0.36), LAKE: 10.18 (+0.89)
Codexis Appoints Biotechnology Industry Veteran, Kathleen Glaub, to Board of Directors
GlobeNewswire - Mon Sep 22, 7:07AM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Kathleen Sereda Glaub to its board of directors. Ms. Glaub's 30-year career in leadership positions with drug development and technology companies will bring strong company-building and business strategy experience to the Codexis board.
CDXS: 3.42 (+0.07)
Analyzing the Market for Cellulosic Ethanol - 2014
M2 - Wed Sep 17, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/38rww8/analyzing_the) has announced the addition of the "Analyzing the Market for Cellulosic Ethanol - 2014" report to their offering. This report is a complete handbook on this dynamic fuel source and its position in the global energy scenario. The report builds on the global energy industry and the consumption patterns which are fed by the traditional sources like Oil, Coal, Natural Gas, Nuclear Energy and Hydroelectricity. The report also presents a track on the global energy consumption patterns along with the resources being used for them. Taking into consideration the revenue cycles in the global energy markets, the report explains the revenue derived from these demand patterns from traditional sources as well as hydroelectric and wind energy. The report further also details each source individually. Taking a contrasting view point the report presents an in depth analysis of the global energy crisis and the growing recognition of unconventional energy sources for arresting this crisis. Key Topics Covered: A. Executive Summary B. Analyzing the Global Energy Industry C. Revenue Returns on Global Energy Markets D. Global Energy Demand & Supply Dynamics E. Looking at the Global Energy Crisis F. Emergence of Ethanol as an Energy Source G. Introduction to Cellulosic Ethanol H. Analyzing the Major Conversion Technologies: Producing Ethanol from Cellulosic Feedstocks I. Analyzing Ethanol Production from Different Feedstocks J. Analyzing the Utility of Ethanol in Transportation K. Commercializing Cellulosic Ethanol L. Factors Impact Growth of the Industry M. Challenges & Issues Facing the Industry N. Technological Patterns Prominent in the Industry O. Role of Industrial Biotechnology in the Development of Cellulosic Ethanol P. Production Patterns Q. Influence of Cellulosic Ethanol on the Farm Economy R. Ethanol Production and Use - Impact on the Economy S. Analyzing the Economics of Ethanol Production T. Analyzing the Regulatory Framework U. Government Incentives & Support Mechanisms V. Leading Industry Players - Abengoa Bioenergy Corporation - Archer Daniels Midland Co. - Aventine Renewable Energy Holdings - Cargill - Codexis, Inc - Dyadic International, Inc - Genencor International - Green Plains Renewable Energy. - Iogen Corporation - Lignol - Mascoma Corporation - NatureWorks, LLC - Novozymes - Pacific Ethanol, Inc. - Renova Energy (Wyoming Ethanol) - SunOpta - Tate & Lyle - The Andersons Inc. - U.S. BioEnergy Corporation - VeraSun Energy Corporation - Verenium - Xethanol BioFuels, LLC For more information visit http://www.researchandmarkets.com/research/38...lyzing_the
ADM: 48.10 (+0.66), GPRE: 25.50 (-0.56), CDXS: 3.42 (+0.07)
Global Synthetic Biology Market Forecasts and Opportunities, 2020
M2 - Tue Sep 02, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnnz65/global_synthetic) has announced the addition of the "Global Synthetic Biology Market (Products, Technologies, Applications and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. Global synthetic biology market was valued at $3.0 billion in 2013 and it is estimated to reach $38.7 billion by 2020, growing at a CAGR of 44.2% during the forecast period. Synthetic biology is a novel field that finds its origin at the intersection of biology and engineering. It involves designing and construction of biological systems or devices that can be applied in varied domains to get specified results. It's a multidisciplinary effort made by scientists to understand the functioning of biological organisms, cells & genes and implementation of artificial genetic processes to give specific characteristics to an organism. It can even be used to develop a completely new biological system. Assistance from government and private organizations, rising number of entities conducting research and declining cost of DNA sequencing and synthesizing are key driving factors of the market. Governments are providing funds to research organizations, assisting them to find novel applications of synthetic biology. Bio-safety & bio-security issues, ethical issues and regulations are key retraining factors of the market. The fact that synthetic biology can be misused has raised concerns all around the world. Further, there are possibilities of accidental release of pathogens or genetically modified organisms into free atmosphere. Report Scope Key Deliverables Market by Products - Enabling Products - DNA Synthesis - Oligonucleotide Synthesis - Enabled Products - Pharmaceuticals - Chemicals - Biofuels - Agriculture - Core Products - Synthetic DNA - Synthetic Genes - Synthetic Cells - XNA - Chassis Organisms Market by Technology - Enabling Technology - Genome Engineering - Microfluidics technologies - DNA synthesis & sequencing technologies - Bioinformatics technologies - Biological components and integrated systems technologies - Enabled Technology - Pathway engineering - Synthetic microbial consortia - Biofuels technologies Market by Application Research & Development - Chemicals - Agriculture - Pharmaceuticals & Diagnostics - Biofuels - Others (Environment, Biotechnology & Biomaterials, etc.) Companies Mentioned - Algenol Biofuels - BASF - BioAmber - BioSearch Technologies - Butamax Advanced Biofuels - Codexis Inc. - Dupont - GEN9 Inc. - Gensript Corporation - Origene Technologies - Synthetic Genomics For more information visit http://www.researchandmarkets.com/research/jn..._synthetic
CDXS: 3.42 (+0.07)
Codexis Reports Financial Results for the Second Quarter of 2014
GlobeNewswire - Wed Aug 06, 3:02PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced its financial results for the second quarter ended June 30, 2014.
CDXS: 3.42 (+0.07)
5 Stocks Ready for Breakouts
at The Street - Mon Aug 04, 9:14AM CDT
These stocks are within range of triggering breakout trades.
BLUE: 90.70 (+0.93), TSLA: 203.77 (+0.89), ZPIN: 16.16 (-0.16), OVTI: 27.30 (unch), CDXS: 3.42 (+0.07), ATRO: 57.27 (+2.72)
